English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAmong the large volume of data on numerous aspects of headache shared at the meeting were several reports related to clinical trial and real-world experiences with a new class of medication for migraine, the monoclonal antibodies that block calcitonin gene-related peptide. This new class of medication – also known as calcitonin gene-related peptide (CGRP)s – is the first developed specifically for and targeting the underlying biology of migraine.
The news and reviews journal,Practical Neurology®, asked attendees how having these new medications for just over a year had changed their clinical practice. Answers appear in the regularly occurring Convention Question feature in the September issue.
“This is an unmatched era for headache disorders, “said Peter Goadsby, MD, PhD, FAHS, director of the NIHR Wellcome Trust at the King’s College Clinical Research Facility in London, professor of Neurology at the University of California, San Francisco and President-elect of the American Headache Society, “New research and continued treatment advancements are providing the community with a better understanding of migraine and offer patients much-needed hope.”
Respondents to Practical Neurology shared their feelings that, within their own practices, new medications improved clinical care, changed how they thought about headache disorders, and made their work more enjoyable.
Craig McChesney, group publisher for Practical Neurology® said,“The enthusiasm and excitement expressed reflects the desire headache specialists have to provide the best possible care for their patients, and how satisfying it can be when that occurs.”
The next AHS clinical symposium is The 2019 Scottsdale Headache Symposium November 21-24 2019 in Scottsdale, AZ. The 62ndAnnual Scientific Meeting of the AHS will be held June 4-7, 2020 in San Diego, CA.
ABOUT PRACTICAL NEUROLOGY
Launched in 2002, Practical Neurology® is uniquely dedicated to providing concise practical reviews, case reports, and news about recent advances in the field to help neurology professionals provide the best possible clinical care using up-to-date information. With a distinguished medical editorial board and peer-reviewed content, we publish 9 issues per year and have a U.S. circulation of over 18,000 physicians.
For more information about Practical Neurology or the Convention Question, contact Anne M. Sydor, Editor in Chief: [email protected].
ABOUT THE AMERICAN HEADACHE SOCIETY
The American Headache Society (AHS) is a professional society of healthcare providers dedicated to the study and treatment of headache and face pain. The Society’s objectives are to promote the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders. Educating physicians, health professionals and the public and encouraging scientific research are the primary functions of this organization. AHS activities include an annual scientific meeting, a comprehensive headache symposium, regional symposia for neurologists and family practice physicians, and publication of the journal Headache. More information can be found at www.americanheadachesociety.org. In 2010 AHS founded the American Migraine Foundation (AMF) to provide access to information and resources for individuals living with migraine, as well as their loved ones. AMF is dedicated to the advancement of research and awareness surrounding migraine, with a mission to mobilize a community for patient support and advocacy, as well as drive and support impactful research that translates into treatment advances for patients with migraine and other disabling diseases that cause severe head pain. Patients can learn more, find help and get connected by visiting www.americanmigrainefoundation.org.
scraped from https://www.newswise.com/articles/experts-share-clinical-perspectives-on-new-class-of-migraine-medications
